Skip Nav Destination
Issues
1 March 2018
-
Cover Image
Cover Image
Epidemiological evidence implicates obesity and the deposition of excess visceral adipose tissue (VAT) in increasing the risk of different cancers, including breast cancer, and cancers of prostate, colon, and esophagus. Cancer is the second foremost cause of death globally, and obesity may contribute to 20% of all cancer-related deaths in the United States. As previously demonstrated by this group, fibroblast growth factor-2 (FGF2) released from VAT induced malignant transformation of non-tumorigenic epithelial cells. At present, there is no preventive measure available in the clinic to prevent VAT/obesity-induced malignant transformation and early-stage cancers.
However, Chakraborty and colleagues describe a possible therapeutic approach by administering a bromodomain inhibitor, I-BET 762 (beginning on page 129). The study demonstrated that VAT and FGF2 upregulate c-Myc protein expression and inhibition of c-Myc at the transcriptional level attenuates malignant transformation. I-BET 762 is currently in clinical trials for the treatment of cancers. Therefore, understanding the critical molecular mechanisms associated with I-BET 762-induced attenuation of transformation may offer a new therapeutic approach to prevent obesity-associated cancers. The cover immunofluorescent image shows overexpressed nuclear c-Myc (in red) in JB6 P+ mouse epidermal cells treated with VAT. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Editorial
Research Articles
Effects of Black Raspberry on Dibenzo[a,l]Pyrene Diol Epoxide Induced DNA Adducts, Mutagenesis, and Tumorigenesis in the Mouse Oral Cavity
Kun-Ming Chen; Joseph B. Guttenplan; Yuan-Wan Sun; Timothy Cooper; Nora A.E. Shalaby; Wieslawa Kosinska; Gabrielle Benitez; Cesar Aliaga; Junjia Zhu; Jason Liao; Krishne Gowda; Shantu Amin; Gary Stoner; Karam El-Bayoumy
Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years
Michelle I. Silver; Julia C. Gage; Mark Schiffman; Barbara Fetterman; Nancy E. Poitras; Thomas Lorey; Li C. Cheung; Hormuzd A. Katki; Alexander Locke; Walter K. Kinney; Philip E. Castle
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.